Trial reportBulletin of the World Health Organization2008
A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China.
Trial report in Bulletin of the World Health Organization, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pooled it
- Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials.PLoS neglected tropical diseases · 2014Pooled it
- Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis.PloS one · 2012Pooled it
- Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis.Parasites & vectors · 2011Pooled it
- Trial
- Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2018Trial
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Artemether and Praziquantel: Origin, Mode of Action, Impact, and Suggested Application for Effective Control of Human Schistosomiasis.Tropical medicine and infectious disease · 2018Review
- Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules.Pharmaceuticals (Basel, Switzerland) · 2018Review
- High prevalence of Schistosoma japonicum and Fasciola gigantica in bovines from Northern Samar, the Philippines.PLoS neglected tropical diseases · 2015Article
- Prevention and control of schistosomiasis: a current perspective.Research and reports in tropical medicine · 2014Article
- Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa.PLoS neglected tropical diseases · 2014Article
- New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China.Molecules (Basel, Switzerland) · 2014Review
- Acute schistosomiasis in travelers: 14 years' experience at the Hospital for Tropical Diseases, London.The American journal of tropical medicine and hygiene · 2013Article
- Artemisinin: the gifts from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.Parasitology research · 2012Article
- Pseudotumoral form of neuroschistosomiasis: report of three cases in Ganzi, China.The American journal of tropical medicine and hygiene · 2012Article
- Neuroschistosomiasis.Journal of neurology · 2012Review
- Schistosomiasis research in the dongting lake region and its impact on local and national treatment and control in China.PLoS neglected tropical diseases · 2011Review
- Diagnosis and management of schistosomiasis.BMJ (Clinical research ed.) · 2011Review
- Assessing the impact of misclassification error on an epidemiological association between two helminthic infections.PLoS neglected tropical diseases · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate the safety and efficacy of combining artemether (AM) and praziquantel (PZQ) in different regimens for treating acute schistosomiasis japonica.
methodsWe undertook a randomized, double-blind, placebo-controlled trial within four specialized schistosomiasis hospitals in the Dongting Lake region, Hunan province, China, between May 2003 and December 2005. Study participants were randomized into one of four treatment regimes: group A received 60 mg/kg PZQ + 6 mg/kg AM; group B received 60 mg/kg PZQ + AM placebo; group C received 120 mg/kg PZQ + 6 mg/kg AM; and group D received 120 mg/kg PZQ + AM placebo. All participants were followed up over a 45-day period. The primary endpoint of the trial was human infection status (determined by positive stool examination). Secondary endpoints involved clinical observations and blood biochemistry, including monitoring haemoglobin and alanine aminotransferase levels over time.
findingsTreatment efficacies of the four different treatment regimens were 98.0%, 96.4%, 97.7% and 95.7% for group A, B, C, and D respectively (P > 0.05). The group B had a greater treatment efficacy (96.4%) than the group D (95.7%) (P > 0.05). Group A treatment was better for clearance of fever (P < 0.05) and resulted in a shorter hospitalization time (P < 0.05).
conclusionThis is the first report of a randomized, double-blind, placebo-controlled trial for evaluating combined chemotherapy with AM and two different dosages (60 mg/kg and 120 mg/kg) of PZQ in the treatment of acute schistosomiasis japonica in China. The combination of AM and PZQ chemotherapy did not improve treatment efficacy compared with PZQ alone. PZQ given as a dosage of 60 mg/kg (1 day, 3 x 20 mg/kg doses at 4-5 hour intervals) may be as effective as a dosage of 120 mg/kg (6 days, 20 mg/kg for each day split into 3 doses at 4-5 hour intervals).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.